Zymeworks agrees to buy Theravance Biopharma for $929m

M&A · Partnership
โดย Pharmaceutical Technology·Read original
Summary · why it matters

Zymeworks has agreed to acquire Theravance Biopharma in a cash deal valued at approximately $929 million. Theravance shareholders will receive $17 per share plus a contingent value right entitling them to 80% of net proceeds from any future monetization of ampreloxetine within ten years. The boards of both companies have unanimously approved the transaction, which is expected to close in the second half of 2026, subject to shareholder and regulatory approvals. Financing includes a $350 million note from OMERS Life Sciences and cash from both companies' expected balances at closing.

Impact on stocks 3

Biotech & Genomic Medicine▲ · 2 stocks
Financials▲ · 1 stocks

Off-coverage companies 1

OMERS Life SciencesPrivate▲ Positive
Capitalrelevance

Providing $350 million note financing for the acquisition

© 2026 MarketDXNews